Kromek Group plc (AIM:KMK)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 73.37M |
| Revenue (ttm) | 37.84M |
| Net Income (ttm) | 12.50M |
| Shares Out | 655.10M |
| EPS (ttm) | 0.02 |
| PE Ratio | 5.79 |
| Forward PE | 29.79 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,202,176 |
| Average Volume | 1,698,521 |
| Open | 11.40 |
| Previous Close | 11.20 |
| Day's Range | 10.50 - 11.50 |
| 52-Week Range | 4.70 - 13.00 |
| Beta | 1.27 |
| RSI | 51.62 |
| Earnings Date | Apr 29, 2026 |
About Kromek Group
Kromek Group plc, together with its subsidiaries, develops, manufactures, and sells radiation detection components and bio-detection technology solutions for the advanced imaging, CBRN detection, and biological threat detection markets. It offers civil nuclear radiation detection products, which include gamma radiation and neutron detectors, high-specification, high-resolution devices, components, and software for nuclear detection problems, as well as offers a range of radiation detectors that use cadmium zinc telluride (CZT) or scintillator t... [Read more]
Financial Performance
Financial StatementsNews
Half Year 2026 Kromek Group PLC Earnings Presentation Transcript
Half Year 2026 Kromek Group PLC Earnings Presentation Transcript
Kromek Group Earnings Call Transcript: H1 2026
CZT detector adoption in medical imaging is accelerating, with Kromek positioned to supply 40% of a $400M market by 2030. Profitability has been achieved, growth is underpinned by major contracts, and future expansion will be funded through debt and structured supply agreements.
Kromek Group Earnings Call Transcript: H2 2025
Profitability and revenue growth were driven by the Siemens deal, strong contract wins, and expanding CBRN and biosecurity segments. Gross margin rose to 81%, and the company targets £60M revenue and 30% EBITDA margin by 2030, with continued year-on-year profit expected.
Kromek secures £1.7m UK government contract for nuclear detection
The UK-based radiation detection specialist, has secured a £1.7m contract under the UK Government’s Radiological Nuclear Detection Framework.
Kromek Group Transcript: CMD Q&A 2025
Two clear growth pillars—advanced imaging and CBRN detection—are driving a midterm target of £60 million revenue and 30–35% EBITDA within five years, supported by strong contract wins, stable margins, and disciplined M&A. Focus remains on organic growth, operational excellence, and expanding in key global markets.
Kromek Group Transcript: CMD 2025
Two core segments—Advanced Imaging and CBRN Detection—are positioned for strong growth, supported by proprietary technology, high entry barriers, and robust customer relationships. FY2025 saw a shift to profitability, a strengthened balance sheet, and a clear midterm target of £60M revenue and 30% EBITDA.
SMALL CAP MOVERS: Kromek eyes profitability after £30m Siemens Healthineers deal
Kromek Group left investors cheering this week as it unmasked a road to profitability via a deal with Siemens Healthineers.
Kromek Group Earnings Call Transcript: H1 2025
Revenue grew 5% to £7.1m with gross margin up to 54%, and the business expects record full-year revenue and EBITDA positive results. Advanced imaging and CBRN segments both show strong growth, with robust pipelines and high revenue visibility for the year.
AIM Market Roundup: Mosman Oil, Sancus Lending, Kromek
Mosman Oil, Sancus Lending, Kromek, Futura Medical, Petards are today's biggest risers and fallers on London's AIM market